Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival
Top Cited Papers
- 1 July 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (19), 4330-4337
- https://doi.org/10.1200/jco.2005.05.017
Abstract
Purpose Attempts to improve survival of patients with esophageal cancer have been made using induction chemoradiotherapy (CRT) followed by surgery. A large single-center experience was reviewed to determine which treatment-related variables could predict survival and recurrence. Patients and Methods All patients undergoing esophagectomy between January 1994 and December 2002 were reviewed. Univariate and multivariate analyses were performed using log-rank and Cox proportional hazards models, and survival curves were estimated using the Kaplan-Meier method. Results Of 171 patients with invasive cancer, 131 (77%) underwent preoperative CRT. The average age was 60 years, and most patients were male (85%). Operations performed included Ivor-Lewis (60%), transhiatal (8%), three-hole (23%), or left thoracoabdominal (8%) esophagectomy. Perioperative mortality rate was 5%. Median overall survival (OS) of the entire group was 33 months, and the 5-year OS rate was 26%. Induction CRT was associated with a 33% 5-year survival rate compared with 11% for surgery alone (P = .43). Patients downstaged to pathologic stage 0 or I had an improved OS and disease-free survival (DFS) compared with those patients who were not downstaged (P = .022). Additionally, the ability to perform an R0 resection was a significant factor for OS and DFS (n = 130; P < .0001 and P <.0002, respectively). Conclusion Response to CRT and the ability to perform an R0 resection are associated with significantly improved survival in patients with esophageal carcinoma.Keywords
This publication has 17 references indexed in Scilit:
- Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: A phase I reportThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancerInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Factors predictive of complete resection of operable esophageal cancer: a prospective studyThe Annals of Thoracic Surgery, 2003
- Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective TrialJournal of Clinical Oncology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Treatment Outcomes of Resected Esophageal CancerAnnals of Surgery, 2002
- Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the EsophagusNew England Journal of Medicine, 1997
- A Comparison of Multimodal Therapy and Surgery for Esophageal AdenocarcinomaNew England Journal of Medicine, 1996
- Pre‐operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre‐operative radiotherapy and chemotherapy. The second scandinavian trial in esophageal cancerWorld Journal of Surgery, 1992
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusNew England Journal of Medicine, 1992